Ketamine, an anesthetic that blocks NMDA receptors, may offer new ways to manage Alzheimer's disease by improving communication between brain cells and reducing inflammation. The review describes how ketamine could help with depression and agitation that often accompany Alzheimer's, though these results are still preliminary and more research is needed to confirm its safety and effectiveness.
Buprenorphine therapy is a primary treatment for opioid addiction and chronic pain, but a one-size-fits-all approach is no longer adequate. This review compares two dosing strategies: microdosing, which uses minimal doses to reduce dependence and side effects, and macrodosing, which uses higher doses that are effective but raise concerns about misuse and overdose. Tailoring therapy to individual patient needs is essential for addressing contemporary healthcare challenges in pain management and opioid addiction.